ERBISOL ULTRApharm, solution for injections, ampules 2ml #10

ERBISOL ULTRApharm, solution for injections, ampules 2ml #10

$84.00

A characteristic feature of ERBISOL® products is the original mechanism of action, according to which they act not so much on the disease as on the whole organism, activating the controlling systems of the body responsible for the search for and elimination of pathological changes. One of the main such monitoring systems is the immune system. The drugs specifically activate the immune system, the effectiveness of which manifests itself primarily through the action of the macrophage link, which contributes to the repair of damaged cells and the restoration of the functional activity of organs and tissues, and also through the N- and T-killers responsible for the destruction of abnormal cells and tissues. ERBISOL® products in their composition contain low-molecular “signal” fragments of membrane glycoproteins performing the function of “markers of the physiological state of cells”, which, in pathological disturbances of homeostasis, activate the natural evolutionarily formed control systems of the body responsible for the search for and elimination of pathological changes in organs and tissues.

  • Description
  • Additional information
  • Doses and Uses
  • Shipping & Payment
  • Reviews (0)

Description

ERBISOL ULTRApharm. A characteristic feature of ERBISOL® products is the original mechanism of action, according to which they act not so much on the disease as on the whole organism, activating the controlling systems of the body responsible for the search for and elimination of pathological changes. One of the main such monitoring systems is the immune system.

The drugs specifically activate the immune system, the effectiveness of which manifests itself primarily through the action of the macrophage link, which contributes to the repair of damaged cells and the restoration of the functional activity of organs and tissues, and also through the N- and T-killers responsible for the destruction of abnormal cells and tissues.

ERBISOL® products in their composition contain low-molecular “signal” fragments of membrane glycoproteins performing the function of “markers of the physiological state of cells”, which, in pathological disturbances of homeostasis, activate the natural evolutionarily formed control systems of the body responsible for the search for and elimination of pathological changes in organs and tissues.

One such system is the immune system.

ACTIVE SUBSTANCES ERBISOL ULTRApharm: a complex of natural non-protein low-molecular organic compounds of non-hormonal origin, derived from animal embryonic tissue, contains oligopeptides, glycopeptides, nucleotides, amino acids.
AUXILIARY SUBSTANCES: р-р 0,9% of sodium chloride isotonic.

SPECIFICITY of IMMUNOMODULATING PROPERTIES of ERBISOL® products:

  • activate macrophage cells involved in the repair of damaged cells and regeneration of organs and tissues with the restoration of their functional activity;
  • activate the killer series cells (N- and T-killers and cytotoxic T-lymphocytes CD8 ), responsible for the destruction of damaged cells that are unable to regenerate, or abnormal cells (mutant, malignant, virus carriers, etc.) and tissues;
  • are immunocorrectors: they normalize the activity of Th1 and Th2 lymphocytes and restore the balance of cytokines, thereby harmonizing the state of cellular and humoral immunity, as well as inhibiting the course of autoimmune and allergic processes.

Accelerate the destruction of abnormal and the restoration of damaged cells and tissues. ERBISOL® products ONLY affect unbalanced systems, affected organs and tissues and remain practically indifferent to a healthy organism without causing side effects, i.e. drugs are harmless, do not lead to drug poisoning in case of overdoses or long-term use. Excellent means for disease prevention.
Increase the protective and adaptive functions of the body.
Will help to realize your physiological potential for a full-fledged way of life.

ERBISOL ULTRApharm more activates the cells of the killer series (N-, T-killers, cytotoxic T-lymphocytes CD8 ), as well as Th1 lymphocytes and, to some extent, macrophages; induces the synthesis of a-, b- and g-interferons, interleukin (IL) -2 and IL-12, tumor necrosis factor, is an effective immunocorrector.
The main direction of the action of Erbisol® ULTRApharm is associated with the enhancement of antiviral and antitumor protection of the body.

The exclusive rights to ERBISOL® products are protected in 20 countries of the world on the basis of international applications PCT / UA93 / 00003 and PCT / UA93 / 00004, including:
European Patent No. 0673652, No. 0673653, US Patents No. 08/397287, No. 08/397288, No. 2041715, No. 2041715 of Ukraine, No. 2164 of Ukraine, No. 2163, of Belarus No. 2039, No. 2040, of Poland No. 173321, No. 173302, of Bulgaria No. 61679 , No. 61680, ….

PHARMACOLOGICAL PROPERTIES ERBISOL ULTRApharm:
Pharmacodynamics. Pharmacological activity of the drug is determined by the content of low-molecular biologically active peptides in it, which activate the natural, evolutionarily formed control systems of the body, responsible for the search and elimination of pathological changes. Erbisol ULTRApharm activates the immune system to accelerate the restoration of damaged and destroy abnormal cells and tissues. The main immunomodulatory effect of the drug is primarily due to the effect on NK cells (CD316 56 ) and T-killers (CD3 16 56 ), responsible for the destruction of damaged cells that are unable to regenerate, or abnormal cells (mutant, malignant cells, virus carriers, etc.) and tissues, as well as through the macrophage link responsible for the repair of damaged cells and restoration of the functional activity of organs and tissues. At the same time, Erbisol ULTRApharm has an immunocorrective effect and, in case of immune status disorders, contributes to its normalization, activating T-lymphocytes, Th1-helpers and T-killers, which is important for restoring the balance between cellular and humoral immunity in cancer and allergic processes. Depending on the state of the body’s immune system, the drug also corrects the level of some other immunity factors: it induces the synthesis of α-, β-, γ-interferon, tumor necrosis factor, interleukin (IL) -2 and IL-12, and inhibits the synthesis of IL-10. Erbisol ULTRApharm potentiates the action of antibiotics, exogenous interferons and simultaneously reduces their toxic side effects.

INDICATIONS:

  • diseases of bacterial etiology – chronic nonspecific lung diseases during exacerbation and remission;
  • diseases of viral etiology – acute and chronic viral hepatitis B, chronic viral hepatitis C; acute and chronic forms of diseases caused by viruses of the herpes family;
  • Oncology – oncological diseases of the digestive tract, primary liver cancer and metastatic liver damage, brain and lung tumors.

CONTRAINDICATIONS: Individual intolerance of the drug.
SIDE EFFECTS:

  • Erbisol ULTRApharm is well tolerated by patients with no allergic reactions. However, in some cases, during the first 2-5 days of taking the drug, there may be an exacerbation of the chronic inflammatory process, which should not be considered as a negative phenomenon, because in most cases it is a stage of the medical process. During clinical trials, as well as during the application of the drug in clinical practice, allergic reactions were not noted, but the risk of their development is not completely excluded, namely: skin rash, itching sensation.
  • When applying an intensive care course with intravenous drip administration of Erbisol ULTRApharm in the first days of admission, it is possible to raise blood pressure and body temperature, which need to be normalized. If the patient’s condition is severe and the body temperature continues to rise, then the next 5-day cycle should be carried out with IM injection of the drug (2 times a day for 4 ml in the morning and in the evening daily for 5 days).

STORAGE CONDITIONS: At a temperature of 4-12°C (39-53°F). During storage, opalescence may occur.


Additional information

Weight 150 g
Forms of release

Solutions for injections

Volume / Weight

2 ml #10

Packing

Ampoules

Manufacturer

ERBIS

Country/Region of Manufacture

Ukraine

APPLICATION:

  • in the treatment of chronic nonspecific lung diseases Erbisol ULTRAfarm is administered intravenously to adults 2 ml each, diluted with 0.9% sodium chloride isotonic to 20 ml, jet daily in the evening for 10 days or in/m 2 times a day for 2 ml in the morning and in the evening daily for 10 days. The course dose is 10-20 ampoules of 2 ml each. During the exacerbation of the disease, complex therapy is used, and during the remission period, Erbisol ULTRAfarm is prescribed as a monotherapy.
  • In the treatment of diseases caused by viruses of the herpes family, the drug Erbisol ULTRAfarm is administered iv in 2 ml, diluted with 0.9% solution sodium chloride to 20 ml in jet at night every 48 hours for 20 days or in/m 2 ml in the evening every day for 20 days, or 2 times a day for 2 ml in the morning and in the evening every day for 10 days. The course dose is 10-20 ampoules of 2 ml.
  • When lesions of the herpes family of internal organs and systems are affected, Erbisol ULTRAfarm is given intravenous injection of 2 ml diluted with 0.9% solution sodium chloride to 20 ml in a jet daily in the evening for 20 days, and then to prevent relapses – within 20 days of 2 ml in the evening in/m every 48 hours, or / m 2 times a day for 2 ml in the morning and evening every day for 20 days, and then to prevent relapses – within 20 days of 2 ml in the evening in/m every 48 hours. The course dose is 30-50 ampoules of 2 ml. In the acute period of the disease the drug is prescribed as part of complex therapy, and during the period of remission Erbisol ULTRAfarm is used as a monotherapy.
  • In the complex therapy of acute viral hepatitis B, Erbisol ULTRAfarm is given intravenously with 2 ml, diluted with r-rum 0.9% sodium chloride to 20 ml in a jet evening in the evening for 20 days and then for 20 days in 2 ml in the evening in/m every 48 hours, or / m 2 times a day for 2 ml in the morning and in the evening every day for 20 days, and then for 20 days for 2 ml in the evening in/m every 48 hours. The course dose is 30-50 ampoules of 2 ml.
  • In the complex treatment of chronic viral hepatitis C and B, Erbisol ULTRAfarm is given intravenously with 2 ml, diluted with 0.9% sodium chloride isotonic solution to 20 ml, jet daily in the evening for 20 days, or in/m 2 times 2 ml in the morning and in the evening daily for 20 days, and then for 20 days for 2 ml in the evening in/m every 48 hours. The course dose is 30-50 ampoules of 2 ml. After 40-60-day break, it is necessary to conduct repeated courses of treatment, the number of which is determined by the severity of the pathological process.
  • In cancer diseases between courses of chemotherapy or radiotherapy, immunotherapy courses are conducted in which Erbisol ULTRAfarm is used in 4 cycles (subcourses), each of which includes a 5-day daily administration of the drug and a 2-day break during which the administration of chemotherapy is prescribed: in/v jet 2 ml, diluted 0.9% solution sodium chloride to 20 ml daily for 5 days, then after 2 days break continue in the same way the following cycles (subcourses) or in/m 2 times a day for 2 ml in the morning and evening every day in for 5 days, then after 2 days of interruption, the following cycles (subcourses) continue in the same way. The course dose is 20-40 ampoules of 2 ml.

SPECIAL INSTRUCTIONS. During pregnancy and lactation, Erbisol ULTRAfarm should be given only if, in the opinion of the doctor, the benefit of the application exceeds the potential risk to the fetus / child. Children. In children under the age of 18 years experience is not available. Erbisol ULTRAFARM does not affect the reaction rate when driving vehicles or working with other mechanisms.
INTERACTIONS. Erbisol ULTRAfarm enhances the effect of antibacterial agents. For effective implementation of directed immunomodulatory action, Erbisol ULTRAfarm should not be used concomitantly with alcohol (it neutralizes the reparative effect of macrophages), and it is also not recommended to use immunomodulators that stimulate humoral immunity. Incompatibility. Do not mix when administered with other medicines. When diluting, apply only the r-ry, which are indicated in the APPLICATION section. OVERDOSE. Short-term increased fatigue, which does not require specific therapy, is possible.

STANDART SHIPPING WORLDWIDE
WEIGHT (kg) COST ($US) ESTIMATED

DELIVERY TIME

TRACKING
0 - 0.199 6.50 15 - 21 working days Available
0.200 - 0.250 8.00 15 - 21 working days Available
0.251 - 0.500 14.00 15 - 21 working days Available
0.501 - 1.000 20.00 15 - 21 working days Available
1.000 - 2.000 25.00 15 - 21 working days Available

PAYMENT

  • We accept Visa, MasterCard via AdvCash & Payeer (there are problems with the possibility).
  • We accept SEPA, BACS.
  • We accept RIA.
  • We accept Cryptocurrency.
  • PayPal.

Depending on the method of payment, additional Fees / VAT are charged.

And also there is a system of bonuses that you can spend on your next purchases.

Reviews

There are no reviews yet.


Only logged in customers who have purchased this product may leave a review.

You've just added this product to the cart: